EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lifestyle-associated hyperglycemia and aberrant TSH glycoforms in aggressive thyroid carcinoma: glycosylation-mediated mechanisms in treatment resistance hyperglycemia, TSH glycoforms & thyroid cancer

Arya P. R., Mehta Vedant Kamal, Kaushik Joshi, Chinmai Jagadish, Souwarna Jamadar, Prashant Tiwari

Frontiers in Oncology · 09.11.2026 · 16

DOI: 10.3389/fonc.2026.1968674 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 09.11.2026. Verfasst von Arya P. R. und 5 weiteren Autor:innen. Die Arbeit nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review examines the critical intersection between lifestyle-associated hyperglycemia and aggressive thyroid carcinoma, with a particular focus on the role of aberrant thyroid-stimulating hormone (TSH) glycosylation. Chronic hyperglycemia, a characteristic of metabolic disorders such as type 2 diabetes, contributes to a pro-oxidative and pro-inflammatory tumor microenvironment. We propose that this metabolic stress enhances the hexosamine biosynthetic pathway, which may result in abnormal structural remodeling of TSH, specifically hypersialylation and increased N-glycan branching. We hypothesize that these altered TSH glycoforms dynamically interact with the TSH receptor. Due to their prolonged circulatory half-life, they may redirect canonical signaling toward sustained, atypical modulation of oncogenic networks, notably the PI3K/Akt/mTOR and MAPK pathways. These proposed signaling alterations could potentially contribute to tumor cell proliferation, epithelial-mesenchymal transition, immune evasion, and potential resistance to multimodal therapies in advanced thyroid carcinomas. These glycomic alterations may represent potential biomarker candidates; however, their diagnostic and prognostic utility remains clinically unvalidated. These findings provide a rationale for investigating whether metabolic regulation and glycosylation-targeted approaches could contribute to future strategies for overcoming treatment resistance in aggressive thyroid carcinomas.

Zitieren

APA

R., A. P., Kamal, M. V., Joshi, K., Jagadish, C., Jamadar, S., & Tiwari, P. (2026). Lifestyle-associated hyperglycemia and aberrant TSH glycoforms in aggressive thyroid carcinoma: glycosylation-mediated mechanisms in treatment resistance hyperglycemia, TSH glycoforms & thyroid cancer. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1968674

Vancouver

R. AP, Kamal MV, Joshi K, Jagadish C, Jamadar S, Tiwari P. Lifestyle-associated hyperglycemia and aberrant TSH glycoforms in aggressive thyroid carcinoma: glycosylation-mediated mechanisms in treatment resistance hyperglycemia, TSH glycoforms & thyroid cancer. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1968674

BibTeX
@article{R2026,
  author = {R., Arya P. and Kamal, Mehta Vedant and Joshi, Kaushik and Jagadish, Chinmai and Jamadar, Souwarna and Tiwari, Prashant},
  title = {Lifestyle-associated hyperglycemia and aberrant TSH glycoforms in aggressive thyroid carcinoma: glycosylation-mediated mechanisms in treatment resistance hyperglycemia, TSH glycoforms & thyroid cancer},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1968674}
}
Kostenlos starten →